9dmg: Difference between revisions

Line 1:

~~'''Unreleased structure'''~~

~~The entry~~ 9dmg is ~~ON HOLD until Paper Publication~~

==Human muscle nAChR apo state==

~~Authors~~: Li, H., ~~Hibbs~~, R.E.

== Structural highlights ==

<table><tr><td colspan='2'>[[9dmg]] is a 5 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9DMG OCA]. For a guided tour on the structure components use [https://proteopedia.org/fgij/fg.htm?mol=9DMG FirstGlance].

~~Description~~: ~~Human muscle nAChR apo state~~

</td></tr><tr id='method'><td class="sblockLbl">[[Empirical_models|Method:]]</td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 2.05Å</td></tr>

[[Category: ~~Unreleased~~ Structures]]

<tr id='ligand'><td class="sblockLbl">[[Ligand|Ligands:]]</td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=POV:(2S)-3-(HEXADECANOYLOXY)-2-[(9Z)-OCTADEC-9-ENOYLOXY]PROPYL+2-(TRIMETHYLAMMONIO)ETHYL+PHOSPHATE'>POV</scene></td></tr>

[[Category: ~~Li, H~~]]

<tr id='resources'><td class="sblockLbl">Resources:</td><td class="sblockDat">[https://proteopedia.org/fgij/fg.htm?mol=9dmg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9dmg OCA], [https://pdbe.org/9dmg PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9dmg RCSB], [https://www.ebi.ac.uk/pdbsum/9dmg PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9dmg ProSAT]</td></tr>

[[Category: ~~Hibbs, R.E~~]]

</table>

== Disease ==

[https://www.uniprot.org/uniprot/ACHA_HUMAN ACHA_HUMAN] Postsynaptic congenital myasthenic syndromes;Lethal multiple pterygium syndrome. The disease is caused by mutations affecting the gene represented in this entry. The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry.

== Function ==

[https://www.uniprot.org/uniprot/ACHA_HUMAN ACHA_HUMAN] After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.

__TOC__

</StructureSection>

[[Category: Homo sapiens]]

[[Category: Large Structures]]

[[Category: Hibbs RE]]

[[Category: Li H]]

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 9dmg is ON HOLD  until Paper Publication
+==Human muscle nAChR apo state==
+<StructureSection load='9dmg' size='340' side='right'caption='[[9dmg]], [[Resolution|resolution]] 2.05&Aring;' scene=''>
-Authors: Li, H., Hibbs, R.E.
+== Structural highlights ==
+<table><tr><td colspan='2'>[[9dmg]] is a 5 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9DMG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9DMG FirstGlance]. <br>
-Description: Human muscle nAChR apo state
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 2.05&#8491;</td></tr>
-[[Category: Unreleased Structures]]
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=POV:(2S)-3-(HEXADECANOYLOXY)-2-[(9Z)-OCTADEC-9-ENOYLOXY]PROPYL+2-(TRIMETHYLAMMONIO)ETHYL+PHOSPHATE'>POV</scene></td></tr>
-[[Category: Li, H]]
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9dmg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9dmg OCA], [https://pdbe.org/9dmg PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9dmg RCSB], [https://www.ebi.ac.uk/pdbsum/9dmg PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9dmg ProSAT]</span></td></tr>
-[[Category: Hibbs, R.E]]
+</table>
+== Disease ==
+[https://www.uniprot.org/uniprot/ACHA_HUMAN ACHA_HUMAN] Postsynaptic congenital myasthenic syndromes;Lethal multiple pterygium syndrome. The disease is caused by mutations affecting the gene represented in this entry.  The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs.  The disease is caused by mutations affecting the gene represented in this entry.  The disease is caused by mutations affecting the gene represented in this entry.
+== Function ==
+[https://www.uniprot.org/uniprot/ACHA_HUMAN ACHA_HUMAN] After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
+__TOC__
+</StructureSection>
+[[Category: Homo sapiens]]
+[[Category: Large Structures]]
+[[Category: Hibbs RE]]
+[[Category: Li H]]